The liquidity puzzle in interval funds

---

1. Key Themes

Theme 1: Evergreen Fund Redemptions Are a Feature, Not a Bug — But Disclosure Is Still Broken

Outflows from interval and evergreen funds are being treated as a crisis, but the mechanics are functioning as designed. The real problem is that investors don't understand what they signed up for.

"Redemptions limited to a certain percentage of an evergreen fund's net assets are by design. If a fund offers to redeem 5% at a quarterly cadence, and investor redemption requests exceed this limit but the fund still meets the 5% target, then things are functioning as designed."

"Funds already file repurchase data, it just lives across regulatory filings most investors will never open. Performance is front and center on every fact sheet. Redemption results should be too."

---

Theme 2: Scale Wins in Healthcare PE — Emerging Managers Are Being Squeezed Out

In private markets broadly, and healthcare specifically, capital is consolidating into fewer, larger vehicles managed by established players. Emerging managers are being left behind.

"Capital flowed to established managers at the expense of emerging and smaller funds... top managers in healthcare PE have steadily increased fund sizes as the strategy matures, with the largest funds now entering upper middle-market and mega-fund categories."

"These large raises brought total commitments to $18.3 billion, in line with the elevated figures of the past three years, even as fund count fell 47.6% year-over-year."

---

Theme 3: Life Sciences VC Is at a Cyclical Low — LP Appetite Suppressed by Exit Drought

The IPO window closure has created a feedback loop: no exits → no distributions → no LP re-ups → fewer fund closes.

"For life sciences VC, 2025 was one of the weakest years on record, as a largely shut IPO window and limited distributions left LPs with little incentive to re-up. Just 33 funds closed, a third of the prior five-year average."

---

Theme 4: Agtech VC Is Quietly Recovering, Driven by Dual-Use and Robotics

After a prolonged downturn, agtech is seeing renewed VC interest — not from traditional agriculture angles, but from defense-adjacent and automation tailwinds.

"VC funding for the agtech market is seeing a mild comeback, driven by renewed appetite for dual-use tech and advances in robotics — with overall deal value reaching $1.5 billion in Q1."

---

Theme 5: The 2026 IPO Market Is More Concentrated Than Anticipated

Despite broader optimism about a tech IPO revival, the pipeline may be dominated by just a handful of names.

"The 2026 IPO market was supposed to be tech's comeback story. Instead, three companies might swallow the entire pie, according to our recent analyst note."

---

2. Contrarian Perspectives

Evergreen Fund Outflows Are Not a Systemic Crisis

Consensus view frames recent redemption episodes as a warning sign about product design or portfolio quality. PitchBook pushes back, arguing outflows are statistically normal and structurally expected — and that comparisons to public fund behavior validate this.

"Research from our Morningstar colleagues indicates that outflows are inevitable: Nearly 80% of funds with a five-year history have experienced over 20% outflows in a given 12-month period."

"Concerns around portfolio quality leading to redemptions are absolutely valid, and it would be careless to dismiss them. However, in our opinion, some details regarding the mechanics of redemptions are not adequately explained."

---

Healthtech VC Is Underperforming Despite AI Hype — The Narrative Is Ahead of the Capital

There is enormous media and strategic attention on AI in healthcare, yet fundraising tells a very different story. LP appetite remains suppressed by unresolved legacy overhang from pandemic-era digital health bets.

"Despite significant attention around AI in healthcare, the strategy raised just $2 billion across 19 funds in 2025. Pandemic-era digital health startups have struggled to exit, limiting distributions and dampening LP appetite for new commitments."

---

Life Sciences LP Pullback Is Market-Wide, Not a Sector Rejection

The sharp drop in life sciences fund closes could be misread as a loss of conviction in biotech. The data suggests otherwise — specialists are holding their share of total venture dollars, meaning the retreat is proportional and macro-driven.

"Life science specialists' share of total venture dollars held steady in 2025, suggesting the pullback is market-wide rather than strategy-specific."

---

3. Companies Identified

---

4. People Identified

---

5. Operating Insights

For Fund Managers: Redemption Transparency Is a Competitive Differentiator

Interval and evergreen fund managers who proactively surface redemption results — not just performance — alongside their fact sheets will build greater LP trust. The current norm of burying repurchase data in regulatory filings is a reputational liability.

"Performance is front and center on every fact sheet. Redemption results should be too."

---

For Healthcare Investors: Track Record Is the New Moat in a Compressed LP Market

In a fundraising environment where fund count dropped nearly 50% YoY, LPs are concentrating allocations in managers who have demonstrated the ability to navigate biotech cycles. New entrants face a near-impossible fundraising environment without exits to show.

"As in PE, LPs favored managers with proven ability to navigate biotech's cycle, with four funds accounting for two-thirds of the $10.6 billion committed."

---

For Agtech Founders: Frame Your Pitch Around Dual-Use and Automation

The recovery in agtech VC is not being driven by traditional food/ag narratives. Startups with robotics applications or dual-use (civilian + defense) relevance are attracting renewed capital. Founders should position accordingly.

"VC funding for the agtech market is seeing a mild comeback, driven by renewed appetite for dual-use tech and advances in robotics."

---

6. Overlooked Insights

PE Q1 2026: Deal Activity Holding, But Fundraising Is Lagging — A Potential Valuation Divergence Ahead

This is briefly flagged but not analyzed in depth. If deal activity continues while fundraising lags, it could signal GPs are deploying existing dry powder aggressively ahead of a tighter capital environment — a dynamic worth monitoring for pricing implications.

"Q1 was marked by steady deal activity but lagging fundraising — leaving the industry at a crossroads."

---

European AI Startup Formation Has Nearly Doubled in Five Years

Mentioned only as a chart callout, but the scale is striking: nearly 11,000 AI startups now exist in Europe — nearly twice the count from five years ago. This represents a significant and underappreciated competitive and investment surface area relative to US-centric AI narratives.

"There are almost 11,000 AI startups in Europe, nearly twice as many as five years ago."